T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

Investigator Award has been awarded to two surgeon-scientists at the National Cancer Centre Singapore (NCCS) to pursue novel research in liver cancer and head and neck cancers. Globally, liver cancer ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

A new study reveals that even low-dose, chronic exposure to air pollution can trigger liver inflammation, fibrosis, and metabolic disruptions, increasing the risk of fatty liver disease and other ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

The lack of NHS funded testing for this type of cancer in Scotland means patients are denied targeted treatments unless they ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

The year 2024 was momentous for metabolic dysfunction-associated steatotic ... 60 weeks to investigate the progression from MASLD to hepatocellular carcinoma.